scholarly journals Long-term direct and indirect costs of ulcerative colitis in a privately-insured United States population

2020 ◽  
Vol 36 (8) ◽  
pp. 1285-1294
Author(s):  
Dominic Pilon ◽  
Zhijie Ding ◽  
Erik Muser ◽  
Camilo Obando ◽  
Jennifer Voelker ◽  
...  
Epilepsia ◽  
2009 ◽  
Vol 51 (5) ◽  
pp. 838-844 ◽  
Author(s):  
Jasmina I. Ivanova ◽  
Howard G. Birnbaum ◽  
Yohanne Kidolezi ◽  
Ying Qiu ◽  
David Mallett ◽  
...  

2011 ◽  
Vol 14 (3) ◽  
pp. A4
Author(s):  
A. Kaltenboeck ◽  
S. Foster ◽  
N. Thomas ◽  
J. Ivanova ◽  
M. Diener ◽  
...  

2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Joelle Constantin ◽  
Petar Atanasov ◽  
Daniel Wirth ◽  
Andras Borsi

Abstract Background The economic burden of ulcerative colitis (UC), specifically related to indirect costs, is not extensively documented. Understanding and quantifying it is required by health care decision makers. Aim To assess the impact of indirect costs of UC in observation studies. Method A systematic literature search was conducted in MEDLINE®, Embase® and Cochrane Library to capture all relevant publications reporting outcomes on absenteeism, presenteeism and productivity losses in moderate to severe UC. Eligibility criteria for inclusion into the review were established using a predefined PICOS scheme. All costs were adjusted to 2017 currency values (USD dollars, $). Results In total, 18 studies reporting data on indirect costs were included in the analysis. Absenteeism costs were classified into three categories: sick leave, short-term and long-term disability. Most of the studies captured absenteeism costs related specifically to sick leave, which was experienced on average by 10 to 24% patients with UC. Only three studies captured presenteeism costs, as these are difficult to measure, however costs ranged from 1602 $ to 2947 $ per patient year. The proportion of indirect costs accounted for 35% of total UC costs (Total UC costs were defined as the sum of healthcare costs, productivity costs and out-of-pocket costs). Discussion A limited number of studies were identified describing the indirect costs in patients with moderate to severe UC. Insufficient data on different components of costs allowed a limited analysis on the impact of indirect costs in patients with UC. Further studies are needed to gain an understanding of the influence of UC on patients’ functional abilities.


2015 ◽  
Vol 18 (6) ◽  
pp. 457-465 ◽  
Author(s):  
Zheng-Yi Zhou ◽  
Marion A. Koerper ◽  
Kathleen A. Johnson ◽  
Brenda Riske ◽  
Judith R. Baker ◽  
...  

Depression ◽  
2019 ◽  
pp. 1-14
Author(s):  
Madhukar H. Trivedi ◽  
Tracy L. Greer ◽  
Taryn L. Mayes

Major depressive disorder (MDD) is a serious, debilitating, life-shortening illness that affects many persons of all ages and backgrounds. The point prevalence of MDD is high (2.3–3.2% in men; 4.5–9.3% in women) and the lifetime risk for MDD is 7% to 12% for men and 20% to 25% for women. MDD is a disabling disorder that costs the United States over $200 billion per year in direct and indirect costs. Depression also has detrimental effects on all aspects of social functioning (e.g., self-care, social role, and family life, including household, marital, kinship, and parental roles). While there have been several treatments that are efficacious, many individuals suffering from depression experience lifelong challenges due to the often chronic and episodic nature of the disease. Identifying strategies to find the right treatments for the right patients is critical.


Sign in / Sign up

Export Citation Format

Share Document